BOLD Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 13:33):

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA...

Stats
Today's Volume	94 205.00
Average Volume	258 783
Market Cap	213.49M
EPS	-1.000 ( 2019-11-07 )
Last Dividend	0 ( N/A )
Next Dividend	0 ( N/A )
P/E	0
ATR14	0.0640 (0.67%)

Insider Trading

Date	Person	Action	Amount	type
2020-01-15	Soloway Thomas P	Sell	3 829	Stock Option (Right to Buy)
2020-01-15	Soloway Thomas P	Sell	183 384	Common Stock
2020-01-15	Soloway Thomas P	Sell	6 263	Stock Option (Right to Buy)
2020-01-15	Soloway Thomas P	Sell	73 781	Stock Option (Right to Buy)
2020-01-15	Soloway Thomas P	Sell	75 000	Stock Option (Right to Buy)

INSIDER POWER
0.00
Last 99 transactions
Buy: 1 180 833 \| Sell: 2 761 220

Volume Correlation

Long: -0.21 (neutral)

Short: 0.53 (weak)

Signal:(47.314) Neutral

Boundless Bio, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Boundless Bio, Inc. Correlation - Currency/Commodity

-0.07
( neutral )

-0.53
( weak negative )

0.80
( moderate )

0.34
( neutral )

0.75
( moderate )

-0.31
( neutral )

Boundless Bio, Inc. Financials

Annual	2023
Revenue:	0
Gross Profit:	-957 000 (0.00 %)
EPS:	-2.22

FY	2023
Revenue:	0
Gross Profit:	-957 000 (0.00 %)
EPS:	-2.22

FY	2022
Revenue:	0
Gross Profit:	-942 000 (0.00 %)
EPS:	-2.06

FY	2018
Revenue:	0.00
Gross Profit:	0.00 (0.00 %)
EPS:	-2.93

Financial Reports:

No articles found.

Boundless Bio, Inc.

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.